Search clinical trials for: CHF6001 DPI

Total 1302 results

Chiesi Farmaceutici S.p.A.

Completed

Safety, Tolerability and Efficacy of 28-day Inhaled CHF 6001 DPI in COPD Patients

COPD

United Kingdom, Ireland
Chiesi Farmaceutici S.p.A.

Completed

Evaluation of the Absolute Bioavailability and Mass Balance of CHF6001 (Tanimilast) in Healthy Subjects

Chronic Obstructive Pulmonary Disease (COPD) | COPD

United Kingdom
Chiesi Farmaceutici S.p.A.

Recruiting

A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp® 500µg) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR) (PILLAR)

Chronic Obstructive Pulmonary Disease

Bulgaria, United States, Argentina, Austria, Bosnia and Herzegovina, Chile, Croatia, Czechia, Estonia, Germany, Greece, Hungary, Israel, Latvia, Mexico, Netherlands, New Zealand, North Macedonia, Poland, Romania, Russian Federation and more
Chiesi Farmaceutici S.p.A.

Recruiting

A 52-week, Placebo-controlled Study to Evaluate the Efficacy and Safety of 2 Doses of CHF6001 DPI (Tanimilast), as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis (PILASTER) (PILASTER)

Chronic Obstructive Pulmonary Disease

Bulgaria, United States, Albania, Argentina, Australia, Austria, Bosnia and Herzegovina, Chile, China, Czechia, Georgia, Germany, Greece, Hungary, Israel, Italy, Mexico, Netherlands, New Zealand, North Macedonia, Poland, Romania, Russian... and more
Memorial Sloan Kettering Cancer Center
Weill Medical College of Cornell University

Completed

MRI and Diffusion Imaging of Eloquent Brain Areas to Optimize Brain Tumor Resection Planning

Brain Cancer

United States
Chiesi Farmaceutici S.p.A.

Completed

A Study to Evaluate the Efficacy After Allergen Challenge, Safety and Tolerability of Inhaled CHF6001 DPI in Asthmatics (CHF6001_POC2)

Asthma

United Kingdom
Chiesi Farmaceutici S.p.A.
Quintiles, Inc.

Completed

Pharmacokinetic Interaction and the Safety of Inhaled CHF5259 and CHF6001

Copd

United Kingdom
Chiesi Farmaceutici S.p.A.

Completed

PK of CHF6001 in Subjects With Mild, Moderate and Severe Renal Impairment vs. Healthy Volunteers

Chronic Obstructive Pulmonary Disease

Bulgaria
Chiesi Farmaceutici S.p.A.

Recruiting

Efficacy and Safety of Tanimilast in Asthmatics uNcontrolled on ICS-containinG backgrOund Maintenance Therapy (TANGO)

Uncontrolled Asthma

Argentina, Bulgaria, Czechia, Georgia, Germany, Hungary, Italy, Korea, Republic of, Latvia, Lithuania, Poland, Romania, South Africa, Spain
Umeå University
County Council of Norrbotten, Sweden

Completed

Lifestyle Intervention in Primary Health Care - the Björknäs Study

Hypertension | Obesity | Type 2 Diabetes | Dyslipidemia

Sweden
Chiesi Farmaceutici S.p.A.

Completed

Clinical Study to Investigate the Pharmacokinetics, Safety and Tolerability Following Single Administration of CHF6001 in Subjects With Mild, Moderate and Severe Liver Impairment in Comparison With Matched Healthy Control Subjects

Chronic Obstructive Pulmonary Disease

Bulgaria
GlaxoSmithKline

Completed

Comparative Study of ELLIPTA Dry Powder Inhaler (DPI) Versus DISKUS DPI Used With HandiHaler DPI in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States
Debiopharm International SA

Recruiting

A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors

Pancreatic Ductal Adenocarcinoma (PDAC) | Colorectal Cancer (CRC) | Clear Cell Renal Cell Cancer (ccRCC)

France, Australia
Chiesi Farmaceutici S.p.A.

Completed

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Inhaled CHF6001 (CHF6001Ext)

Chronic Obstructive Pulmonary Disease

United Kingdom
GlaxoSmithKline

Completed

An Open-label Study to Evaluate Correct Use and Ease of Use of the ELLIPTA DPI in Pediatric Subjects With Asthma

Asthma

Canada, United States
Sanofi

Completed

A PK Comparability Study of Two Different Amlitelimab Drug Products in Healthy Participants

Healthy Volunteers

United States
Celon Pharma SA
National Center for Research and Development, Poland

Completed

Efficacy, Safety and Pharmacokinetic Study of Inhaled Esketamine in Treatment-resistant Depression

Major Depressive Disorder

Poland
AlgiPharma AS
AlgiPharma Australia Pty. Ltd.

Unknown

A Phase 2b Randomised, Placebo Controlled Study of OligoG in Patients With Cystic Fibrosis

Cystic Fibrosis

Australia
Celon Pharma SA
National Center for Research and Development, Poland

Completed

Efficacy, Safety and Pharmacokinetic Study of Inhaled Esketamine in Treatment-resistant Bipolar Depression

Bipolar Depression

Poland
Nocion Therapeutics

Completed

Placebo-controlled, Single and Multiple Dose Study in Healthy Volunteers and Refractory Chronic Cough Patients to Assess the Safety, Tolerability, and Pharmacokinetics of Two Formulations of NTX-1175

Refractory Chronic Cough

United States
Celon Pharma SA
National Center for Research and Development, Poland

Completed

Safety and Pharmacokinetic Study of Inhaled Esketamine in Healthy Volunteers

Healthy Volunteers

Poland
University of North Carolina, Chapel Hill
University of Texas at Austin

Completed

Evaluation of a Dry Powder Aerosol Dispersion Mechanism by Radiolabeling Techniques (DPI)

Adult Healthy Volunteers

United States
Forest Laboratories
PPD

Terminated

Study of the Safety and Efficacy of Apadenoson for Detection of Myocardial Perfusion Defects Using SPECT MPI (ASPECT)

Coronary Artery Disease

United States, Brazil
Chiesi Farmaceutici S.p.A.

Completed

An Open Label Placebo Study to Assess the Inhalation Profile in Asthmatic Patients Using the Nexthaler® Dry Powder Inhaler (DPI) Device (NEXThalerPIF)

Asthma

Italy
Chiesi Farmaceutici S.p.A.

Completed

Investigation of the Effect of Inhibition of CYP3A4/5 by Itraconazole on the PK of CHF6001 (Tanimilast)

Chronic Obstructive Pulmonary Disease

Belgium
Forest Laboratories
PPD

Terminated

Study of the Safety and Efficacy of Apadenoson for Detection of Myocardial Perfusion Defects Using SPECT MPI (ASPECT2)

Coronary Artery Disease

United States, Argentina, Belgium, Brazil, Netherlands
Chiesi Farmaceutici S.p.A.

Completed

An Open Label Placebo Study To Assess The Inhalation Profile Obtained By Acoustic Monitoring In COPD Patients Using The NEXThaler DPI (PIF3)

COPD

Italy
Medical College of Wisconsin
University of Wisconsin, Milwaukee; Children's Hospital and Health System Foundation... and other collaborators

Completed

Evaluating a New Way to Prepare Parents of Hospitalized Children for Discharge and Management of Child at Home

Patient Discharge

United States
GlaxoSmithKline

Completed

A Study to Investigate the Efficacy, Safety, and Tolerability of Repeat Doses of Inhaled GSK2269557 in Adults With Persistent, Uncontrolled Asthma

Pulmonary Disease, Chronic Obstructive

Germany
AstraZeneca
Parexel

Terminated

Evaluation of AZD8154 Concentrations in Blood

Asthma

Germany
AstraZeneca
Parexel

Completed

A Study to Assess the Efficacy and Safety of Multiple Dose Levels of AZD7594 Administered Once Daily by Inhalation in Asthmatic Subjects

Asthma

United States, Germany, South Africa, Ukraine, Japan, Hungary, Poland, Bulgaria
Sanofi
Regeneron Pharmaceuticals

Completed

Comparison of the Pharmacokinetics and Safety of Two SAR231893 (REGN668) Drug Products in Healthy Subjects

Healthy

United States
GlaxoSmithKline

Completed

Pharmacokinetic Profile of Four Formulations of Fluticasone Furoate (FF) Using Unit Dose Dry Powder Inhaler (UD-DPI) Compared With FF ELLIPTA® Presentation

Asthma

Australia
Chiesi Farmaceutici S.p.A.

Completed

Efficacy of Fixed Combination of Beclomethasone Dipropionate (BDP) + Formoterol Fumarate (FF) + Glycopyrronium Bromide (GB) (CHF 5993)Administered Via Dry Powder Inhaler (DPI) in Chronic Obstructive Pulmonary Disease (COPD) (TRI-D)

Chronic Obstructive Pulmonary Disease

Bulgaria
BeyondSpring Pharmaceuticals Inc.
Covance; ICON plc

Completed

Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 3 (Protective-1)

Chemotherapy-induced Neutropenia

China, Russian Federation, United States, Ukraine
GlaxoSmithKline

Completed

Study to Evaluate Safety, Tolerability and Pharmacokinetics of GSK2269557 to Japanese Healthy Subjects

Pulmonary Disease, Chronic Obstructive

Japan
University of California, Davis

Completed

Casinomacropeptide and Satiety (CMP2)

Appetite Disorders | Lack of Satiety | Excess Intake of Macronutrients

United States
GlaxoSmithKline

Completed

Safety and Efficacy Study of Fluticasone Furoate/Vilanterol (FF/VI) Fixed Dose Combination (FDC) Compared to FF Alone in Subjects With Asthma

Asthma

United States, Argentina, Japan, Poland, Canada, Russian Federation, Spain, Germany, Hungary, South Africa, Italy, Mexico, Romania, Bulgaria, China, Lithuania
Swiss Paraplegic Research, Nottwil

Completed

Exploring Functional Paralysis With Advanced Magnetic Resonance Modalities

Paralysis | Functional Neurological Symptom Disorder | Conversion Disorder With Weakness/Paralysis

Switzerland
AstraZeneca

Completed

A Clinical Trial in Healthy Volunteers and Patients With Mild Asthma to Investigate a New Medicine (AZD4604) for the Treatment of Asthma

Asthma

United Kingdom
University of Edinburgh

Completed

Does Disciplined Personal Involvement Precede Change in CBASP?

Chronic Depression

United Kingdom
Stanford University
Patient-Centered Outcomes Research Institute; San Jose State University

Completed

A Patient-Centered Strategy for Improving Diabetes Prevention in Urban American Indians

Diabetes Mellitus, Type 2 | Metabolic Syndrome | Insulin Resistance

United States
Johns Hopkins Bloomberg School of Public Health
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Completed

Pilot Trial of a Novel Cooking Skills Intervention (DPPCooks) to Prevent Diabetes (DPPCooks)

Pre-diabetes

United States
Medisol Development Kft.
University of Debrecen; St. Borbala Hospital; Pest County Pulmonology Hospital; Medical Centre Hungarian Defence Forces and other collaborators

Active, not recruiting

Breathing Parameter Measurements for Lung Deposition Simulation (CHOICE)

Asthma | COPD

Hungary
Beta Pharma, Inc.

Completed

A Phase I Study to Determine the Effect of Food on the Pharmacokinetic Profile of BPI-7711

NSCLC

China
PreCision Dermatology, Inc.

Unknown

An Evaluation of PDI-320 in Comparison to Its Monads in Adults With Rosacea

Rosacea

United States
University College, London

Unknown

Donor Lymphocyte Infusion After Stem Cell Transplant in Treating Patients With Haematological Cancers (ProT4)

Lymphoma | Leukemia | Myelodysplastic Syndrome | Myeloma | Graft Versus Host Disease

United Kingdom
Kaiser Permanente

Completed

Evaluating the Implementation of the Diabetes Prevention Program in an Integrated Health System

Diabetes

United States
DermBiont, Inc.

Suspended

A Trial to Evaluate the Safety and Efficacy of DBI-001 Gel, DBI-002 Gel, and Aqueous Gel in Subjects With Onychomycosis

Onychomycosis

United States
University of Texas Southwestern Medical Center
NeurOptics Inc.

Completed

Inter-Device Reliability of the NPi-300 Pupillometer (TRIPLE)

Critical Illness | Neuropathy

United States

3

Subscribe